Rafael Amado Sells 9,910 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Rafael Amado sold 9,910 shares of Zai Lab stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $202,064.90. Following the sale, the insider directly owned 59,761 shares in the company, valued at $1,218,526.79. This trade represents a 14.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Rafael Amado also recently made the following trade(s):

• On Friday, March 13th, Rafael Amado sold 2,957 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total value of $55,088.91.

Zai Lab Price Performance

Shares of ZLAB opened at $20.41 on Friday. The firm has a market cap of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $44.34. The company has a 50 day simple moving average of $18.67 and a two-hundred day simple moving average of $21.75.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The company had revenue of $127.60 million during the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, sell-side analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC purchased a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,754 shares of the company’s stock, valued at approximately $331,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on ZLAB. JPMorgan Chase & Co. reduced their price objective on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. UBS Group began coverage on shares of Zai Lab in a report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. Finally, Cantor Fitzgerald dropped their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.